Organon Future Growth
Future criteria checks 1/6
Organon's revenue and earnings are forecast to decline at 0.06% and 7.1% per annum respectively. EPS is expected to decline by 7.4% per annum. Return on equity is forecast to be 84.3% in 3 years.
Key information
-7.1%
Earnings growth rate
-7.4%
EPS growth rate
Pharmaceuticals earnings growth | 21.2% |
Revenue growth rate | -0.06% |
Future return on equity | 84.3% |
Analyst coverage | Good |
Last updated | 18 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 6,529 | 1,025 | 1,103 | 1,078 | 6 |
12/31/2025 | 6,528 | 871 | 1,033 | 983 | 7 |
12/31/2024 | 6,399 | 915 | 701 | 1,129 | 6 |
9/30/2024 | 6,409 | 1,301 | 646 | 946 | N/A |
6/30/2024 | 6,346 | 1,000 | 787 | 1,066 | N/A |
3/31/2024 | 6,347 | 1,047 | 458 | 761 | N/A |
12/31/2023 | 6,263 | 1,023 | 538 | 799 | N/A |
9/30/2023 | 6,150 | 585 | 424 | 669 | N/A |
6/30/2023 | 6,168 | 754 | 320 | 725 | N/A |
3/31/2023 | 6,145 | 746 | 431 | 849 | N/A |
12/31/2022 | 6,174 | 917 | 431 | 858 | N/A |
9/30/2022 | 6,292 | 1,011 | 138 | 638 | N/A |
6/30/2022 | 6,355 | 1,107 | 343 | 689 | N/A |
3/31/2022 | 6,365 | 1,304 | 564 | 1,077 | N/A |
12/31/2021 | 6,304 | 1,351 | 1,970 | 2,458 | N/A |
9/30/2021 | 6,314 | 1,525 | 2,370 | 2,841 | N/A |
6/30/2021 | 6,327 | 1,762 | 2,304 | 2,761 | N/A |
3/31/2021 | 6,258 | 1,917 | 2,772 | 3,025 | N/A |
12/31/2020 | 6,532 | 2,256 | 1,932 | 2,187 | N/A |
12/31/2019 | 7,777 | 3,306 | 2,675 | 2,767 | N/A |
12/31/2018 | 9,777 | 2,153 | 3,586 | 3,687 | N/A |
12/31/2017 | 10,500 | 1,801 | N/A | 3,419 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 7XP's earnings are forecast to decline over the next 3 years (-7.1% per year).
Earnings vs Market: 7XP's earnings are forecast to decline over the next 3 years (-7.1% per year).
High Growth Earnings: 7XP's earnings are forecast to decline over the next 3 years.
Revenue vs Market: 7XP's revenue is expected to decline over the next 3 years (-0.06% per year).
High Growth Revenue: 7XP's revenue is forecast to decline over the next 3 years (-0.06% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 7XP's Return on Equity is forecast to be very high in 3 years time (84.3%).